Search

Issue
Title
Authors
Rare histological subtypes of bladder cancer in clinical practice: a case series
Paychadze A.A., Golubeva S.A., Kamalova M.A.
Clinical case of complications of immunotherapy – encephalitis
Lyadova M.A., Kuchevskaya O.A., Kulikova E.A.
Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation (Russian Translation of Cochrane Plain Language Summary – PLS)
Alexandrova E.G.
Neuroendocrine carcinoma of the prostate (review of the literature)
Abbasova D.V., Polikarpova S.B., Kozlov N.A., Baranova M.P., Kovalenko I.P., Ignatova E.I.
Modern possibilities of immunotherapy in the treatment of extensive-stage small cell lung cancer: experience of durvalumab application. Case report
Zhabina A.S., Moiseenko F.V., Volkov N.M., Abduloeva N.K., Moiseenko V.M.
Treatment of advanced small cell lung cancer. Clinical case and literature review
Menshikov K.V., Sultanbaev A.V., Musin S.I., Menshikova I.A., Nasretdinov A.F., Sultanbaeva N.I.
Differential diagnosis and treatment of rare forms of primary peritoneal tumors – solitary fibrous and desmoplastic small round cell tumors
Abdullaev A.G., Kozlov N.A., Schakhpazyan N.K., Tsigankova A.V.
Clinical case of long-term use of durvalumab in the treatment of advanced small-cell lung cancer
Statsenko G.B., Kurakin V.I., Plokhotenko I.V.
Extrapulmonary small cell carcinoma. Literature review
Orel N.F., Poddubnaya I.V.
The first experience of immunotherapy application of ipilimumab in combination with chemotherapy of small-cell lung cancer in the Russian population. Analysis of the combined data of two centers, participating in the multicenter randomized phase III study СА 184-156
Kuzminov A.E., Gorbunova V.A., Poddubskaya E.V., Bagrova S.G., Baranova M.P., Laktionov K.K.
The use of atezolizumab in combination with chemotherapy in first-line of metastatic small cell lung cancer. Case report
Ognerubov N.A., Antipova T.S.
The comparative pharmacoeconomic analysis of tyrosine kinase inhibitor Iressa® (gefitinib) with TKI Giotrif® (afatinib) as first-line therapy for patients with advanced non-small cell lung cancer associated with mutations in the epidermal growth factor receptor
Ryazhenov V.V.
1 - 12 of 12 Items

Search tips:

  • Search terms are case-insensitive
  • Common words are ignored
  • By default only articles containing all terms in the query are returned (i.e., AND is implied)
  • Combine multiple words with OR to find articles containing either term; e.g., education OR research
  • Use parentheses to create more complex queries; e.g., archive ((journal OR conference) NOT theses)
  • Search for an exact phrase by putting it in quotes; e.g., "open access publishing"
  • Exclude a word by prefixing it with - or NOT; e.g. online -politics or online NOT politics
  • Use * in a term as a wildcard to match any sequence of characters; e.g., soci* morality would match documents containing "sociological" or "societal"

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies